Insight A Conversation with WIT’s ITC Practice Chair: Examining 2024 Trends in Section 337 Investigations
Insights Home Insights Featured Content Q&As Q&A: The Impact of Changes to Federal Rule of Evidence 702 We asked WIT CEO Paul Neale to share his thoughts on the implications of the FRE 702 amendment and the proactive measures attorneys can take to ensure their expert witnesses withstand greater judicial scrutiny. Blog Life Sciences Roundup: Top Insights from Q2 – Q3 Life sciences companies face mounting litigation over patents, products, and pricing practices. Successfully navigating these matters requires expertise from qualified experts and an expert agency focused on arising litigation trends. Check out our insights. Blog ITC Investigation Insights from Q3 – CALJ Cheney Report and More In our effort to help our clients navigate the complexities of this specialized venue, we take a proactive approach to delivering relevant insights, examining trends within the sector with regard to filings, investigation timelines, judge preferences, and more. Let’s explore some of our insights from Q3 and examine WIT’s involvement with the ITC. Case Study- Technology Case Study: Automotive Technology Expert Needed for an IPR Proceeding at the PTAB The petitioner alleged patent infringement involving ETC systems in modern vehicles. The respondent turned to WIT for an expert in automotive control, vehicle electronics, and engineering. Discover how WIT was able to meet the expert need. Q&As Q&A: Trends Shaping Intellectual Property Litigation Today We asked WIT President Michael Connelly to share his thoughts on the critical trends shaping IP litigation today, including the rising complexities of expert witness selection, the evolving role of the ITC, and the strategies needed to address these challenges head-on. Insights & News All Industries Automotive Biotechnology Financial Technology Gaming Healthcare Technology Pharmaceutical Wireless Communications All Trends 5G / 6G Banking Crisis COVID-19 Cryptocurrency Drug and Vaccine Development Election Law and Voting Rights Electric Vehicles FDA-Regulated Drugs and Devices Mobile Gaming Payment Systems Virtual Reality Wearable Devices All Insight Types Archive Article Blog Case Study Case Study- Life Sciences Case Study- Technology Event In the News Other Content Press Release Q&As Report Video Search October 23, 2024 — Blog Life Sciences Roundup: Top Insights from Q2 – Q3 Life sciences companies face mounting litigation over patents, products, and pricing practices. Successfully navigating these matters requires expertise from qualified experts and an expert agency focused on arising litigation trends. Check out our insights. June 18, 2024 — Report A National Study of Community Attitudes Toward Pharmaceutical Companies WIT commissioned the DOAR Research Center to conduct a national study of community attitudes toward pharmaceutical companies and several issues suspected of creating bias. Learn more about their findings. June 12, 2024 — Report Hatch-Waxman Spotlight: Senior Judge Richard Andrews Our latest Hatch-Waxman report provides a comprehensive analysis of Senior Judge Richard Andrews' activity at the United States District Court for the District of Delaware since his appointment in November 2011. Learn more about our findings. October 2, 2023 — Article Expert Perspective: What is Driving Growth and Litigation in the Biotechnology Space? The biotechnology market is headed towards transformational growth as the landscape shifts, resulting from impending patent cliffs, increased M&A activity, and ongoing innovation. WIT biotech expert Peter Lankau provides insights on what's to come in the industry for the remainder of this year and beyond. July 26, 2023 — Blog Big Pharma’s Balancing Act: Navigating Patent Thickets in the Age of Biosimilars Biosimilar patent cases are complex legal battles that require the support of various experts to bolster the nuanced arguments presented by pharmaceutical companies. May 17, 2023 — Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more. April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets. February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP. July 14, 2021 — Blog FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability. June 16, 2021 — Blog Biologics vs. Biosimilars – Driving Innovation, BPCIA Litigation, and a Need for Experts With patents for several existing biological drugs set to expire in the coming decade, biosimilar companies and manufacturers have an opportunity to take advantage. Load More Loading...
Q&As Q&A: The Impact of Changes to Federal Rule of Evidence 702 We asked WIT CEO Paul Neale to share his thoughts on the implications of the FRE 702 amendment and the proactive measures attorneys can take to ensure their expert witnesses withstand greater judicial scrutiny.
Blog Life Sciences Roundup: Top Insights from Q2 – Q3 Life sciences companies face mounting litigation over patents, products, and pricing practices. Successfully navigating these matters requires expertise from qualified experts and an expert agency focused on arising litigation trends. Check out our insights.
Blog ITC Investigation Insights from Q3 – CALJ Cheney Report and More In our effort to help our clients navigate the complexities of this specialized venue, we take a proactive approach to delivering relevant insights, examining trends within the sector with regard to filings, investigation timelines, judge preferences, and more. Let’s explore some of our insights from Q3 and examine WIT’s involvement with the ITC.
Case Study- Technology Case Study: Automotive Technology Expert Needed for an IPR Proceeding at the PTAB The petitioner alleged patent infringement involving ETC systems in modern vehicles. The respondent turned to WIT for an expert in automotive control, vehicle electronics, and engineering. Discover how WIT was able to meet the expert need.
Q&As Q&A: Trends Shaping Intellectual Property Litigation Today We asked WIT President Michael Connelly to share his thoughts on the critical trends shaping IP litigation today, including the rising complexities of expert witness selection, the evolving role of the ITC, and the strategies needed to address these challenges head-on.
October 23, 2024 — Blog Life Sciences Roundup: Top Insights from Q2 – Q3 Life sciences companies face mounting litigation over patents, products, and pricing practices. Successfully navigating these matters requires expertise from qualified experts and an expert agency focused on arising litigation trends. Check out our insights.
June 18, 2024 — Report A National Study of Community Attitudes Toward Pharmaceutical Companies WIT commissioned the DOAR Research Center to conduct a national study of community attitudes toward pharmaceutical companies and several issues suspected of creating bias. Learn more about their findings.
June 12, 2024 — Report Hatch-Waxman Spotlight: Senior Judge Richard Andrews Our latest Hatch-Waxman report provides a comprehensive analysis of Senior Judge Richard Andrews' activity at the United States District Court for the District of Delaware since his appointment in November 2011. Learn more about our findings.
October 2, 2023 — Article Expert Perspective: What is Driving Growth and Litigation in the Biotechnology Space? The biotechnology market is headed towards transformational growth as the landscape shifts, resulting from impending patent cliffs, increased M&A activity, and ongoing innovation. WIT biotech expert Peter Lankau provides insights on what's to come in the industry for the remainder of this year and beyond.
July 26, 2023 — Blog Big Pharma’s Balancing Act: Navigating Patent Thickets in the Age of Biosimilars Biosimilar patent cases are complex legal battles that require the support of various experts to bolster the nuanced arguments presented by pharmaceutical companies.
May 17, 2023 — Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more.
April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets.
February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP.
July 14, 2021 — Blog FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability.
June 16, 2021 — Blog Biologics vs. Biosimilars – Driving Innovation, BPCIA Litigation, and a Need for Experts With patents for several existing biological drugs set to expire in the coming decade, biosimilar companies and manufacturers have an opportunity to take advantage.